Meridian Bioscience, Inc. Reports Unaudited Earnings Results for the First Quarter Ended December 31, 2015; Provides Earnings Guidance for the Full Year Ending September 30, 2016
For the full year ending September 30, 2016, management expects net revenues to be in the range of $195 million to $200 million and per share diluted earnings to be between $0.86 and $0.90. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.0 million at fiscal 2015 year end to approximately 42.2 million at fiscal 2016 year end. The revenue and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2016.